CAMBRIDGE, Mass.–(BUSINESS WIRE)–Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today reported financial results for the third quarter ended September 30, 2026, highlighting recent progress and business updates. “2026 has been a transformative year so far for Obsidian. In the third quarter, we closed an oversubscribed $350
